PMID- 28331683
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1306-0945 (Print)
IS  - 1306-0953 (Electronic)
IS  - 1306-0945 (Linking)
VI  - 11
IP  - 1
DP  - 2015 Jan
TI  - Problems In Determining Her2 Status In Breast Carcinoma.
PG  - 10-16
LID - 10.5152/tjbh.2014.2103 [doi]
AB  - OBJECTIVE: Human epidermal growth factor receptor 2 (HER2) oncoprotein is 
      overexpressed in 15-25% of breast carcinomas and associated with poor outcome. 
      Assessment of HER2 status accurately is important to select patients who will 
      benefit from targeted therapy. MATERIALS AND METHODS: In this study 
      immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were 
      used to determine the HER2 status in 308 breast carcinoma cases of which 129 were 
      consultation. The major problems in determining HER2 status and the reasons of 
      discordant results between methods were discussed. RESULTS: HER2 expression was 
      (-) in 124, (+) in 29, (++) in 92, (+++) in 63 cases. 25 of 76 cases consulted as 
      (++) were evaluated as (++) and 15 of 35 cases consulted as (+++) were evaluated 
      as (+++). HER2 amplification was found in 88 (28.6%) of 308 cases by FISH. 3 of 
      124 (-), 1 of 29 (+), 22 of 92 (++), 62 of 63 (+++) cases were amplified by FISH. 
      The relation between HER2 expression and amplification was statistically 
      significant (p<0.001). Centromere 17 (CEN 17) region amplification was noted in 
      11 cases of which 2 were (+++), 9 were (++). 6 of the 11 cases showed focal low 
      level, 1 of them showed diffuse high level amplification. CONCLUSION: The 
      concordance rate between IHC (+++) cases and FISH was 95.4% for consultation 
      cases, 100% for our cases. The final concordance rate for both case groups was 
      98.4%. The possible reasons of discrepancy were triple negativity, preanalytical 
      and analytical procedures of consultation cases and trucut samples.
FAU - Pala, Emel Ebru
AU  - Pala EE
AD  - Clinic of Pathology, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
FAU - Bayol, Umit
AU  - Bayol U
AD  - Clinic of Pathology, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
FAU - Ozguzer, Alp
AU  - Ozguzer A
AD  - Clinic of Pathology, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
FAU - Kucuk, Ulku
AU  - Kucuk U
AD  - Clinic of Pathology, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
FAU - Akdeniz, Caglar Yildiz
AU  - Akdeniz CY
AD  - Clinic of Pathology, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
FAU - Sezer, Ozlem
AU  - Sezer O
AD  - Clinic of Pathology, Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20150101
PL  - Turkey
TA  - J Breast Health
JT  - The journal of breast health
JID - 101549103
PMC - PMC5351527
OTO - NOTNLM
OT  - Breast cancer
OT  - erbB genes
OT  - fluorescence in situ hybridization
COIS- Conflict of Interest: No conflict of interest was declared by the authors.
EDAT- 2015/01/01 00:00
MHDA- 2015/01/01 00:01
PMCR- 2015/01/01
CRDT- 2017/03/24 06:00
PHST- 2014/06/12 00:00 [received]
PHST- 2014/10/14 00:00 [accepted]
PHST- 2017/03/24 06:00 [entrez]
PHST- 2015/01/01 00:00 [pubmed]
PHST- 2015/01/01 00:01 [medline]
PHST- 2015/01/01 00:00 [pmc-release]
AID - jbh-11-1-10 [pii]
AID - 10.5152/tjbh.2014.2103 [doi]
PST - epublish
SO  - J Breast Health. 2015 Jan 1;11(1):10-16. doi: 10.5152/tjbh.2014.2103. eCollection 
      2015 Jan.